Showing results (51-60 of 112) with videos related to
Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib StudyEdward S Kim, Karen Kelly, Luis G Paz-Ares, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 23, 2025
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief ReportXiuning Le, Christina Baik, Byoung Chul Cho, et al.JTO Clinical and Research Reports|January 10, 2022
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLCD Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, et al.JTO Clinical and Research Reports|November 25, 2022
The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective StudyDavid J Benjamin, Shuai Chen, Joanna B Eldredge, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2023
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung CancersJulia Rotow, Jyoti D Patel, Matthew P Hanley, et al.European Journal of Cancer (Oxford, England : 1990)|May 27, 2026
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARDZofia Piotrowska, Sarah B Goldberg, Jonathan W Goldman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumorsAdil I Daud, Michelle T Ashworth, Jonathan Strosberg, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerNaiyer A Rizvi, Matthew D Hellmann, Julie R Brahmer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2022
Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid TumorsJonathan W Goldman, Sarina A Piha-Paul, Brendan Curti, et al.Lung Cancer (Amsterdam, Netherlands)|September 10, 2021
Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLCNanruoyi Zhou, Maria A Velez, Benjamin Bachrach, et al.Pageof 12